Healthcare Videos
  • All Technology
  • AI
  • Autonomy
  • B2B Growth
  • Big Data
  • BioTech
  • ClimateTech
  • Consumer Tech
  • Crypto
  • Cybersecurity
  • DevOps
  • Digital Marketing
  • Ecommerce
  • EdTech
  • Enterprise
  • FinTech
  • GovTech
  • Hardware
  • HealthTech
  • HRTech
  • LegalTech
  • Nanotech
  • PropTech
  • Quantum
  • Robotics
  • SaaS
  • SpaceTech
AllNewsDealsSocialBlogsVideosPodcastsDigests

Healthcare Pulse

EMAIL DIGESTS

Daily

Every morning

Weekly

Sunday recap

NewsDealsSocialBlogsVideosPodcasts
HealthcareVideosPulsed Field Ablation Shows Early Promise for VT Treatment
HealthcareHealthTech

Pulsed Field Ablation Shows Early Promise for VT Treatment

•February 13, 2026
0
DeviceTalks
DeviceTalks•Feb 13, 2026

Why It Matters

PFA’s ability to cut VT ablation time while maintaining high efficacy could transform care for high‑risk cardiac patients and lower procedural costs.

Key Takeaways

  • •First prospective ventricular pulsed field ablation trial published.
  • •Achieved 98% reduction in VT burden overall post‑procedure.
  • •82% of patients remained VT‑free at six months.
  • •Procedure time potentially cut from four hours to one hour.
  • •Early results suggest safer, faster therapy for high‑risk patients.

Summary

The video discusses the first prospective trial of pulsed‑field ablation (PFA) applied to ventricular tachycardia (VT), a technique previously limited to atrial procedures. Published in Circulation: Arrhythmia and Electrophysiology, the study marks a milestone in expanding PFA to the ventricle.

Results showed a 98% reduction in VT burden measured by ICD therapies and an 82% freedom‑from‑VT rate at six months. Although the cohort was small, the data suggest that PFA can achieve comparable efficacy to conventional radiofrequency ablation while dramatically shortening procedure duration—from roughly four hours to about one hour.

One of the investigators emphasized, “This is the first real publication of a prospective trial of this technology in the ventricle,” noting the “dramatic drop” in arrhythmia episodes. The speaker also highlighted the potential for a safer workflow for critically ill patients who otherwise face lengthy, invasive procedures.

If larger, multicenter trials confirm these findings, PFA could become the new standard for VT ablation, offering faster, less invasive treatment and reducing hospital resource utilization, which would be especially valuable for patients with implantable cardioverter‑defibrillators.

Original Description

In this clip from our FOMO series, Dr. Steven Mickelsen, CEO of Field Medical explains how VT burden is measured in ICD patients before and after ablation and why these early results could shorten VT ablation procedures from hours to about an hour, potentially improving safety for high-risk patients.
Follow https://www.youtube.com/playlist?list=PLaqtOqIjH88nTVs15C_PywOISl8LNcseD to access the full FOMO podcast.
0

Comments

Want to join the conversation?

Loading comments...